Literature DB >> 6444236

T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.

M J Berendt, R J North.   

Abstract

The results of this paper are consistent with the hypothesis that progressive growth of the Meth A fibrosarcoma evokes the generation of a T-cell-mediated mechanism of immunosuppression that prevents this highly immunogenic tumor from being rejected by its immunocompetent host. It was shown that it is possible to cause the regression of large, established Meth A tumors by intravenous infusion of tumor-sensitized T cells from immune donors, but only if the tumors are growing in T-cell-deficient recipients. It was also shown that the adoptive T-cell-mediated regression of tumors in such recipients can be prevented by prior infusion of splenic T cells from T-cell-intact, tumor-bearing donors. The results leave little doubt that the presence of suppressor T cells in T-cell-intact, tumor-bearing mice is responsible for the loss of an earlier generated state of concomitant immunity, and for the inability of intravenously infused, sensitized T cells to cause tumor regression. Because the presence of suppressor T cells generated in response to the Meth A did not suppress the capacity of Meth A-bearing mice to generate and express immunity against a tumor allograft, it is obvious that they were not in a state of generalized immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6444236      PMCID: PMC2185761          DOI: 10.1084/jem.151.1.69

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  Development of concomitant immunity in mice bearing the weakly immunogenic line 1 lung carcinoma.

Authors:  J M Yuhas; N H Pazmiño; E Wagner
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

2.  The development and specific suppression of concomitant immunity in two syngeneic tumour-host systems.

Authors:  K D Chandradasa
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

3.  Importance of thymus-derived lymphocytes in cell-mediated immunity to infection.

Authors:  R J North
Journal:  Cell Immunol       Date:  1973-04       Impact factor: 4.868

4.  Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes.

Authors:  L Milas; N Hunter; K Mason; H R Withers
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

Review 5.  The mechanism of immunological paralysis.

Authors:  D W Dresser; N A Mitchison
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

6.  The effect of tumor size on concomitant tumor immunity.

Authors:  P J Deckers; R C Davis; G A Parker; J A Mannick
Journal:  Cancer Res       Date:  1973-01       Impact factor: 12.701

7.  Influence of tumor antigen on maintenance versus depression of tumor-specific immunity.

Authors:  J Vaage
Journal:  Cancer Res       Date:  1973-03       Impact factor: 12.701

8.  Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue.

Authors:  J Vaage
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

9.  Regulation of the immune response to tumor antigens. III. Characterization of thymic suppressor factor(s) produced by tumor-bearing hosts.

Authors:  M I Greene; S Fujimoto; A H Sehon
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

10.  Enhancing T lymphocytes from tumor-bearing mice suppress host resistance to a syngeneic tumor.

Authors:  A J Treves; C Carnaud; N Trainin; M Feldman; I R Cohen
Journal:  Eur J Immunol       Date:  1974-11       Impact factor: 5.532

View more
  115 in total

Review 1.  Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.

Authors:  Enrico Proietti; Federica Moschella; Imerio Capone; Filippo Belardelli
Journal:  Mol Oncol       Date:  2011-12-03       Impact factor: 6.603

2.  Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.

Authors:  Shawn M Jensen; Christopher G Twitty; Levi D Maston; Paul A Antony; May Lim; Hong-Ming Hu; Ulf Petrausch; Nicholas P Restifo; Bernard A Fox
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

Review 3.  Toll-like receptors in tumor immunotherapy.

Authors:  Chrystal M Paulos; Andrew Kaiser; Claudia Wrzesinski; Christian S Hinrichs; Lydie Cassard; Andrea Boni; Pawel Muranski; Luis Sanchez-Perez; Douglas C Palmer; Zhiya Yu; Paul A Antony; Luca Gattinoni; Steven A Rosenberg; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

4.  Radiation and immunotherapy: a synergistic combination.

Authors:  Anusha Kalbasi; Carl H June; Naomi Haas; Neha Vapiwala
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

5.  Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Authors:  David C Binder; Boris Engels; Ainhoa Arina; Ping Yu; James M Slauch; Yang-Xin Fu; Theodore Karrison; Byron Burnette; Christian Idel; Ming Zhao; Robert M Hoffman; David H Munn; Donald A Rowley; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2013-08       Impact factor: 11.151

6.  Radiation-induced augmentation of the response of A/J mice to SaI tumor cells.

Authors:  R E Anderson; S Tokuda; W L Williams; N L Warner
Journal:  Am J Pathol       Date:  1982-07       Impact factor: 4.307

Review 7.  Lymphocytes in cancer development: polarization towards pro-tumor immunity.

Authors:  Brian Ruffell; David G DeNardo; Nesrine I Affara; Lisa M Coussens
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-11       Impact factor: 7.638

Review 8.  Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

Authors:  M H Geukes Foppen; M Donia; I M Svane; J B A G Haanen
Journal:  Mol Oncol       Date:  2015-10-30       Impact factor: 6.603

Review 9.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

10.  Immunological tolerance and tumor rejection in embryo-aggregated chimeric mice - lessons for tumor immunity.

Authors:  Alexander Y Wagner; Eric Holle; Lori Holle; Xianzhong Yu; Günter Schwamberger
Journal:  BMC Cancer       Date:  2008-12-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.